Creotech Instruments stock: fair value
CRI.WAThe fair value of Creotech Instruments under our model is $65.52, the price is 191% above.
The fair value is an estimate from our model, not a price target.
Daily figure as of 13 Nov 2026
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $43.68 and expensive above $131.04 (uncertainty very high, based on the price swings of the past year).
The two parts of the fair value come to $85.07 (cash-flow model) and $45.97 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 10.8%. At 11.8% the fair value would be $58.40, at 9.8% it would be $76.03.
Where the number comes from
Half from the cash-flow model, half from earnings times the industry P/E (31.3).
Ten-year cash-flow model from smoothed free cash flow and its past growth until it reaches 5.6%. Discounted at 10.8% (government bond yield 5.6% plus beta 0.98 times a risk premium of 5.3%); no analyst estimates were available.
Calculate with your own assumptionsThe calculation step by step
With these figures the cash flow model arrives at $85.07 per share: free cash flow for the next ten years, each year discounted to today at 10.8%, plus the terminal value for the years after. The table explains the calculation; it is not a recommendation.
Calculation as a table
| Year | Free cash flow | Source | Discount factor | Present value (discounted at 10.8%) |
|---|---|---|---|---|
| 2026 | $8.77M | extrapolated at 26.1% | 0.9026 | $7.92M |
| 2027 | $10.52M | extrapolated at 19.9% | 0.8147 | $8.57M |
| 2028 | $12.16M | extrapolated at 15.6% | 0.7354 | $8.95M |
| 2029 | $13.7M | extrapolated at 12.6% | 0.6638 | $9.09M |
| 2030 | $15.13M | extrapolated at 10.5% | 0.5992 | $9.07M |
| 2031 | $16.5M | extrapolated at 9.0% | 0.5408 | $8.92M |
| 2032 | $17.81M | extrapolated at 8.0% | 0.4882 | $8.7M |
| 2033 | $19.1M | extrapolated at 7.2% | 0.4406 | $8.42M |
| 2034 | $20.39M | extrapolated at 6.7% | 0.3977 | $8.11M |
| 2035 | $21.7M | extrapolated at 6.4% | 0.3590 | $7.79M |
| Step | Value |
|---|---|
| Sum of present values (ten years) | $85.53M |
| Terminal value: cash flow 2035 × (1 + 5.6%) / (10.8% − 5.6%) | $438.11M |
| Present value of terminal value (× 0.3590) | $157.28M |
| Equity value (sum plus present value of terminal value) | $242.81M |
| Shares (diluted) | 2.85M |
| Value per share (equity value divided by shares) | $85.07 |
| Earnings per share, last twelve months | $1.47 |
| × 31.3 (industry P/E) | $45.97 |
| Fair value (average of both parts) | $65.52 |
The model uses free cash flow after interest, which belongs to shareholders, discounted at the cost of equity. Net debt is therefore not deducted again.
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = PLN 3.9742)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 1 May 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.